LTS Inaugurates a New Semi-automated Commercial Production Line and Announces Global Manufacturing to Support SorrelTM Wearable Device Market Expansion
Andernach – LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company, today announced the successful commercial validation of a semi-automated production line for the Sorrel™ wearable drug delivery platform. The commercial capacity, located at LTS’s device technology hub in Netanya (Israel), reinforces LTS’ commitment to meeting the increasing demand for its cutting-edge drug delivery solutions. With the expanded capacity, LTS has secured its ability to meet demand several years into the future.
To further enhance its global manufacturing capabilities, LTS also announces plans to expand Sorrel™ production into Western markets, in proximity of its customers in North America and Europe. The first expansion project is underway, with further manufacturing locations under consideration. The company intends to announce more details about capacity and location in the near future, with commercial devices expected to be available from the new production site in a few years.
“The new manufacturing line is just another step in our current manufacturing growth strategy. As part of this strategy, we leverage the Global footprint of LTS to better serve our growing list of Pharma partners, who have an ever-increasing demand for volume and a need for flexibility.” stated Dr. Andrei Yosef, President and General Manager of LTS Device Technologies, LTD.
“The successful commercial validation of our latest SorrelTM production line and the announcement of our plans for manufacturing capabilities globally are significant steps forward for the SorrelTM platform” said Bas van Buijtenen, CEO of LTS. “The increased, global production capacity of our SorrelTM platform reflects our commitment to our partners, while also being a testament to our commitment to improving the lives of patients worldwide”.
About SorrelTM
The Sorrel™ platform is a versatile wearable drug delivery system designed to simplify the administration of complex therapies. By providing patients with a convenient and user-friendly way to receive treatment at home, Sorrel™ is helping to improve patient outcomes and adherence to therapy.
About LTS
We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS. As a trusted technology partner for the pharmaceutical industry, we develop and manufacture innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches (“MAP”) for the transdermal delivery of small and large molecules, biological actives and vaccines. With its SorrelTM wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China.
